ARTV – artiva biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity [Yahoo! Finance]
Form SC 13G/A Artiva Biotherapeutics, Filed by: venBio Global Strategic Fund III, L.P.
Form 10-Q Artiva Biotherapeutics, For: Sep 30
Form 8-K Artiva Biotherapeutics, For: Nov 12
Form 4 Artiva Biotherapeutics, For: Oct 21 Filed by: MOORE ALISON
Form 3 Artiva Biotherapeutics, For: Oct 21 Filed by: MOORE ALISON
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.